PFIZER – Grant Request for Proposals 2026

Pfizer has this program to support research studies that focus on generating evidence on the use of elranatamab in Multiple Myeloma (MM) in the real world/clinical practice setting. The Geographic Scope is in Spain.

Project Types and Areas of Interest

• Real world evidence (RWE) and observational studies assessing safety, effectiveness and treatment patterns
• Comparative and sequencing analyzes evaluating outcomes across prior therapies and lines of treatment
• Subgroup and disparity research focused on populations under represented in clinical trials
• Patient centered outcomes research, including Patient-Reported Outcomes (PROs), caregiver burden and adherence
• Translational and biomarker research to understand mechanisms of response, resistance and relapse

Eligibility

• The institution and PI must be based in Spain
• Only organizations are eligible to receive grants, not individuals or medical practice groups
• If the project involves multiple departments within an institution and/or between different institutions/organizations/associations, all institutions must have a relevant role and the requesting organization must have a key role in the project
• The PI must have a medical or postdoctoral degree (MD, PhD or equivalent) an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy or Social Work
• The applicant must be the PI or an authorized designee of such individual
• The PI must be an employee or contractor of the requesting organization
• Requesting organization must be legally able to receive award funding directly from Pfizer International LLC

Primary Area of ​​Interest: Oncology – Hematologic – RES

Budget

Up to EUR 120.000 per project

Deadline: May 22, 2026